Citing public interest immunity, Homes Victoria has won a bid for Cabinet documents to be kept confidential in a class action levelled by public housing tenants.
Noumi and auditor Deloitte will pay $43 million to resolve a class action alleging the company misled investors about its inventory, and the class action will make a play for a $5 million penalty agreed to in ASIC proceedings.
A judge has approved a settlement in a class action against Monsanto under which group members will get nothing, after he rejected claims that the company’s Roundup weed killer is carcinogenic.
A former director of investment firm Keystone, who is suspected by the corporate regulator of misusing millions in investor funds, has flagged a potential bid to keep his silence in a case by court-appointed receivers.
Homes Victoria says the decision to demolish public housing towers in Melbourne — now the subject of a class action — took residents’ human rights into account, but has no documents to show it.
Homes Victoria’s claim that there are no documents recording its reasons for deciding to demolish and redevelop two public housing towers that housed 1,200 people left a judge “startled”.
A judge has ruled that two Deloitte partners can act as administrators for embattled wealth manager Keystone, replacing two voluntary administrators from KordaMentha, despite an alleged risk of conflict due to past work for the company.
Deciding an “unusually difficult” costs application, a judge has declined to award Monsanto all of its costs for defending a class action alleging its Roundup weed killer is carcinogenic, saying the agrochemical giant should have pushed harder for a split trial.
A judge has signed off on an agreed-to $5 million penalty against Noumi in ASIC proceedings for violating its continuous disclosure obligations and found the food company’s non-disclosures caused it shares to trade at an inflated price.
Plaintiff firm Maurice Blackburn will foot the bill for the unsuccessful class action against Monsanto over weed killer Roundup, but the company’s reluctance to split the trial in two has come back to bite it.